Evolving chemotherapeutics

Bridging Trial Recruiting at Dose Level 4

The bridging PK study of Deflexifol is progressing well. Study chief investigator Associate Professor Daniel Brungs reports that patients are now expected to be recruited to Dose Level 4, subject to approval by the Independent Data Safety Monitor. 14 patients have been treated so far, including 4 at Dose Level 3 without any SAEs. The study appears to reinforce earlier findings about the safety and tolerability of Deflexifol – with patients tolerating 40% higher dosing than Standard of Care to date. The study is expected to finish recruiting patients in the next few months.